INDP Stock Forecast: Indaptus Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.82
−9.90% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$433.2M
Ticker Nerd rank
25/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$1.8M
Net income−$1.8M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.0%
1M
−4.7%
YTD
−3.1%
1Y
+61.1%
From 52W high
−40.6%
From 52W low
+201.3%
$0.94
$4.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Indaptus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
25/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
75
Growth
73
Momentum
53
Volatility
34
Accruals
23
Quality
21
Revisions
20
Issuance
20

Value (75): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INDP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INDP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26INDP

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2024Maxim GroupMaintainsBuy$8.00 → $5.00
16 Oct 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
15 Apr 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2023HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
11 Aug 2023HC Wainwright & Co.ReiteratesBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
4 May 2023HC Wainwright & Co.ReiteratesBuy—
20 Mar 2023HC Wainwright & Co.MaintainsBuy—
8 Mar 2023HC Wainwright & Co.ReiteratesOverweight—
8 Feb 2023HC Wainwright & Co.ReiteratesBuy—
31 Jan 2022HC Wainwright & Co.AssumesBuy$15
19 Oct 2021Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

INDP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INDP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Indaptus Therapeutics, Inc. returned +61.1% against +6.9% for the S&P 500, dividends included.

INDP vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26INDPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INDP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.9×

Cheaper than 44% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−318.0%

Higher than 5% of US stocks

Return on assets
−98.1%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Indaptus Therapeutics, Inc. has a market value of $433.2M and an enterprise value of $410.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$15.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.7M.

  • Shares outstanding: 133.2M.

  • Indaptus Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

INDP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INDPIndaptus Therapeutics, Inc.$433.2M25
IRLAIRulya Therapeutics, Inc.$432.4M33
OCSOculis Holding AG$435.8M30
CAPRCapricor Therapeutics, Inc.$436.5M13
CTMXCytomX Therapeutics, Inc.$438.8M46
ASMBAssembly Biosciences, Inc.$439.7M79
PRTAProthena Corp. Plc$442.5M90

Take a look at INDP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Indaptus Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INDP

How does Ticker Nerd's model rank INDP?

As at 21 Nov 2026, Indaptus Therapeutics, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (75 of 100).

What is the INDP stock forecast for 2030?

No analyst covering Indaptus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDP are extrapolating price history, which says nothing about the business.

How has INDP stock performed over the past year?

Indaptus Therapeutics, Inc. returned +61.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Indaptus Therapeutics, Inc. do?

Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity.

Company

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products for cancer and viral infections. The company’s current work centers on its Decoy platform, a proprietary system designed to activate multiple components of the innate and adaptive immune system while aiming to reduce systemic toxicity. Its lead candidate, Decoy20, is being developed for a range of oncology and infectious disease applications, including solid tumors and chronic viral infections. Indaptus Therapeutics Inc. operates in the biopharmaceutical sector, where it contributes to research-driven drug development with an emphasis on novel immune-activating approaches. Based in New York, the company is primarily engaged in preclinical and clinical-stage development activities rather than commercial product sales.

CEO Mr. Junyi Dai · 5 employees · United States · https://indaptusrx.com